PARDES BIOSCIENCES, INC.

Pardes Biosciences, Inc. (Nasdaq: PRDS) is a clinical-stage antiviral biopharmaceutical company that came to market through a business combination with LifeSci Acquisition 2 Corp, a SPAC sponsored by LifeSci Capital. The S-1 registration statement, filed January 21, 2022, was submitted in connection with the de-SPAC transaction that brought Pardes into the public markets. Founded by veterans of Gilead Sciences, the company was focused on developing oral antiviral therapies targeting COVID-19 and other serious viral pathogens. LifeSci Acquisition 2 Corp completed its SPAC IPO in 2021. For the full filing history, deal timeline, and comparable de-SPAC transaction data, sign up for complete access at SpacDesk.